NICE draft guidance on cannabidiol for Dravet and Lennox-Gastaut syndromes

  • National Institute for Health and Care Excellence

  • curated by Dawn O'Shea
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

NICE has announced its intention to work with GW Pharma to address the issues highlighted by its independent appraisal committee in its evaluation of cannabidiol for treating Dravet and Lennox-Gastaut syndromes.

In new draft guidance, NICE has taken the decision not to recommend the drug (Epidyolex), used with clobazam, for treating Dravet and Lennox-Gastaut syndromes.

Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE, said: “Even though the committee accepted that the evidence shows that cannabidiol with clobazam reduces seizure frequency, its long-term efficacy is unknown, and the committee was not convinced about the way the company had modelled the effect on people living longer or having a better quality of life."

“Based on the evidence presented to it, the committee could not recommend cannabidiol with clobazam as an effective use of NHS resources. However, we are committed to working with the company to resolve the economic modelling issues identified by the committee, and to help them understand what they may need to do to mitigate the cost of cannabidiol to the NHS. Patients, carers and their families deserve no less.”

Consultees, including the company, healthcare professionals and members of the public can comment on the draft recommendations via the NICE website until 16 September. Final guidance is expected to be published in December.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit